Virtuoso Surgical, the developer of miniaturised robotic tools for endoscopic surgery, recently announced that the US Food and Drug Administration (FDA) granted De Novo authorisation for the Virtuoso Endoscopy System.
It is the first device in a new FDA classification, electromechanical surgical systems for endoluminal surgical procedures (robotic instruments passed through an endoscope into the body).
It is authorised for en bloc resection of bladder lesions in adult patients to obtain tissue samples, including detrusor (bladder) muscle, to assist in the diagnostic evaluation of bladder cancer.
The system received FDA Breakthrough Device Designation in September 2025, which FDA grants to devices that may provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases.
Duke Herrell, urologic surgeon and CEO of Virtuoso Surgical, said: ‘This is a major milestone for our team and for patients with bladder cancer. Removing a tumour intact can provide a better tissue specimen, which supports clearer diagnosis and staging. We are excited to give surgeons a new tool for this common, recurrent, and potentially deadly cancer.’
En bloc resection, enabled by Virtuoso’s technology, can remove many tumours in one intact piece or in larger segments (modified en bloc), preserving the tissue and information pathologists need to stage the cancer.
Sam S Chang, Patricia and Rodes Hart Professor of Urologic Surgery and Chief Surgical Officer of Vanderbilt-Ingram Cancer Centre, who previously chaired the American Urological Association’s bladder cancer clinical guideline panel, said: ‘How well a bladder tumour is removed at the initial operation shapes how accurately we can stage the cancer and plan what comes next for the patient.
‘Our current surgical instruments have not significantly changed in more than a century. En bloc tumour resection has been studied in randomised trials and is recognised in international guidelines, but it can be extremely technically demanding with today’s instruments, and adoption has been very limited, especially in the US. A robotic system purpose-built for it, now authorised by the FDA, gives surgeons a meaningful new tool.’
The Virtuoso system places two needle-sized robotic arms at the tip of a rigid endoscope. Made of superelastic concentric nitinol tubes, Virtuoso’s patented robotic arms follow the surgeon's hand motions from a console. One arm can lift and retract tissue and the tumour while the other dissects beneath it, bringing two-handed dexterity to endoscopic surgery through the urethra.
Virtuoso plans a focused US launch at leading urology centres in 2027.
It is investigating whether its miniature tools can be a future platform for other procedures and surgical specialities that use rigid endoscopes and has completed early non-human feasibility work in gynaecology, pulmonary procedures, and neurosurgery.


